Prostate Cancer

Bayer and Orion corporation today announced the upcoming expansion of the global clinical development program for darolutamide (Nubeqa), an oral androgen receptor inhibitor for patients with prostate cancer.

Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer.

Ashley Ross, MD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, gives insight on the potential for PARP inhibitors in earlier disease settings for prostate cancer.

Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.

Ashley Ross, MD, PhD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, discusses the increasingly dynamic treatment landscape in prostate cancer.

A recent study from the University of Texas MD Anderson Cancer Center found that men with localized prostate cancer on active surveillance might benefit from following a Mediterranean-style diet.

Magnetic resonance imaging (MRI) is often used in the diagnosis and management of prostate cancer, but the method frequently underestimates tumor size, a study in the Journal of Urology shows.

Luis Carrascosa, MD, a radiation oncologist at the Florida Cancer Specialists Ocala Cancer Center, discusses new and upcoming trends in radiation therapy for prostate cancer.

Florida Cancer Specialists has integrated SpaceOAR Hydrogel into its armamentarium as a pre-treatment for radiation therapy in prostate cancer patients.

Daniel F. Hayes, MD, offers definitions and an algorithm for clinicians to define clinical utility.

The findings could lead to a precision medicine approach to prostate cancer screening.

Neeraj Agarwal, MD, University of Utah Huntsman Cancer Institute, discusses knowledge gaps and the importance of genomic testing in prostate cancer.

Neeraj Agarwal, MD, University of Utah Huntsman Cancer Institute, shares his experience regarding the prostate cancer patients who could potentially benefit from PARP inhibition.

Congress passes legislation that will delay the start of the Radiation Oncology (RO) Advanced Payment Model; examining the newly identified variant of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19); a study finds Hispanics and those without college degrees most subject to excess death during pandemic.

Samples show certain subgroups of men with prostate cancer are more receptive to radiation therapy; FDA grants emergency use authorization to an at-home coronavirus disease 2019 (COVID-19) test; Anthony Fauci, MD, says COVID-19 herd immunity is possible by spring 2021.

Neeraj Agarwal, MD, a clinician and researcher at the University of Utah Huntsman Cancer Institute, discusses investigational combinations with PARP inhibitors in prostate cancer treatment.

The genes are part of the family that cause cancer cells to grow.

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses ongoing trials of PARP inhibitors as first-line metastatic prostate cancer treatments.

Researchers from the University of California San Francisco published their results in the Journal of Urology.

Neeraj Agarwal, MD, of the University of Utah's Huntsman Cancer Institute, discusses challenges to progress in getting FDA approval for PARP inhibitors in prostate cancer.

Multiple studies have suggested African American men tend to have more aggressive forms of prostate cancer, but a new study suggests that may not translate to a higher risk of death.

The discovery of a genetic signature that correlates with metastasis in prostate cancer could make it much easier for physicians and patients to choose treatment strategies.

Authors in the Journal of Clinical Oncology discuss hypotheses on the differences in mutations and implications for treatment with PARP inhibitors.

Mounting evidence is supporting the use of poly ADP-ribose polymerase (PARP) inhibitors in prostate cancer, according to a new study.

Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.

The therapy is for patients with deleterious or suspected deleterious germline somatic homologous recombination repair (HRR) gene–mutated cancer or for those whose cancer has progressed after prior treatment with enzalutamide or abiraterone.

Germline testing at diagnosis, along with tumor testing, have the potential to identify candidates for investigational poly (ADP-ribose) polymerase (PARP) inhibitors, and updated guidelines call for their expanded use.

The US Preventive Services Task Force (USPSTF) recommends that men aged 55 to 69 make their own decision on whether or not to be screened periodically for prostate cancer after they have had a conversation with their physician on potential benefits and harms.